Inside epoxyeicosatrienoic acids and cardiovascular disease

Frontiers in Pharmacology

Volumn 5, Issue NOV, 2014, Pages

  Tacconelli, Stefania ^a   Patrignani, Paola ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Cytochrome P450; Epoxyeicosatrienoic acids; Epoxygenases; Hypertension; Soluble epoxide hydrolase

Indexed keywords

EID: 84949117241     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00239     Document Type: Short Survey

References (55)

1. Ai, D., Fu, Y., Guo, D., Tanaka, H., Wang, N., Tang, C.,et al. (2007). Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro, and in vivo. Proc. Natl. Acad. Sci. U.S.A. 104, 9018-9023. doi: 10.1073/pnas.0703229104
2. Alonso-Galicia, M., Maier, K. G., Greene, A. S., Cowley, A. W. Jr., and Roman, R. J. (2002). Role of 20-hydroxyeicosatetraenoic acid in the renal, and vasoconstrictor actions of angiotensin II. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283, R60-R68. doi: 10.1152/ajpregu.00664.2001
3. Anandan, S. K., Webb, H. K., Chen, D., Wang, Y. X., Aavula, B. R., Cases, S.,et al. (2011). 1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea. (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia. Bioorg. Med. Chem. Lett. 21, 983-988. doi: 10.1016/j.bmcl.2010.12.042
4. Archer, S. L., Gragasin, F. S., Wu, X., Wang, S., McMurtry, S., Kim, D. H.,et al. (2003). Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12. (-)epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels. Circulation 107, 769-776. doi: 10.1161/01.CIR.0000047278.28407.C2
5. Bellien, J., and Joannides, R. (2013). Epoxyeicosatrienoic acid pathway in human health, and diseases. J. Cardiovasc. Pharmacol. 61, 188-196. doi: 10.1097/FJC.0b013e318273b007
6. Bellien, J., Joannides, R., Richard, V., and Thuillez, C. (2011). Modulation of cytochrome derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases? Pharmacol. Ther. 131, 1-17. doi: 10.1016/j.pharmthera.2011.03.015
7. Catella, F., Lawson, J. A., Fitzgerald, D. J., and Fitzgerald, G. (1990). Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy induced hypertension. Proc. Natl. Acad. Sci. U.S.A. 87, 5893-5897. doi: 10.1073/pnas.87.15.5893
8. Chen, D., Whitcomb, R., MacIntyre, E., Tran, V., Do, Z. N., Sabry, J.,et al. (2012). Pharmacokinetics, and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single-, and multiple-dose studies in healthy human subjects. J. Clin. Pharmacol. 52, 319-328. doi: 10.1177/0091270010397049
9. Chen, Y., Falck, J. R., Manthati, V. L., Jat, J. L., and Campbell, W. B. (2011). 20-Iodo-14,15-epoxyeicosa-8(Z)-enoyl-3-azidophenylsulfonamide: photoaffinity labeling of a 14, 15-epoxyeicosatrienoic acid receptor. Biochemistry 50, 3840-3848. doi: 10.1021/bi102070w
10. Croft, K. D., McGiff, J. C., Sanchez-Mendoza, A., and Carroll, M. A. (2000). Angiotensin II releases 20-HETE from rat renal microvessels. Am. J. Physiol. Renal Physiol. 279, F544-F551.
11. Deng, Y., Theken, K. N., and Lee, C. R. (2010). Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. J. Mol. Cell. Cardiol. 48, 331-341. doi: 10.1016/j.yjmcc.2009.10.022
12. Fatica, R. A., Port, F. K., and Young, E. W. (2001). Incidence trends, and mortality in end-stage renal disease attributed to renovascular disease in the United States. Am. J. Kidney Dis. 37, 1184-1190. doi: 10.1053/ajkd.2001.24521
13. Fava, C., Ricci, M., Melander, O., and Minuz, P. (2012). Hypertension, cardiovascular risk, and polymorphisms in genes controlling the cytochrome P450 pathway of arachidonic acid: a sex-specific relation? Prostaglandins Other Lipid Mediat. 98, 75-85. doi: 10.1016/j.prostaglandins.2011.11.007
14. Fleming, I. (2007). Epoxyeicosatrienoic acids, cell signaling, and angiogenesis. Prostaglandins Other Lipid Mediat. 82, 60-67. doi: 10.1016/j.prostaglandins.2006.05.003
15. Fleming, I. (2008). Vascular cytochrome p450 enzymes: physiology and pathophysiology. Trends Cardiovasc. Med. 18, 20-25. doi: 10.1016/j.tcm.2007.11.002
16. Heizer, M. L., McKinney, J. S., and Ellis, E. F. (1991). 14,15-Epoxyeicosatrienoic acid inhibits platelet aggregation in mouse cerebral arterioles. Stroke 22, 1389-1393. doi: 10.1161/01.STR.22.11.1389
17. Huang, A., Sun, D., Jacobson, A., Carroll, M. A., Falck, J. R., and Kaley, G. (2005). Epoxyeicosatrienoic acids are released to mediate shear stress-dependent hyperpolarization of arteriolar smooth muscle. Circ. Res. 96, 376-383. doi: 10.1161/01.RES.0000155332.17783.26
18. Imig, J. D. (2012). Epoxides, and soluble epoxide hydrolase in cardiovascular physiology. Physiol. Rev. 92, 101-130. doi: 10.1152/physrev.00021.2011
19. Imig, J. D., and Hammock, B. D. (2009). Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat. Rev. Drug Discov. 8, 794-805. doi: 10.1038/nrd2875
20. Imig, J. D., Zhao, X., Capdevila, J. H., Morisseau, C., and Hammock, B. D. (2002). Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39, 690-694. doi: 10.1161/hy0202.103788
21. Jiang, H., McGiff, J. C., Fava, C., Amen, G., Nesta, E., Zanconato, G.,et al. (2013). Maternal, and fetal epoxyeicosatrienoic acids in normotensive, and preeclamptic pregnancies. Am. J. Hypertens. 26, 271-278. doi: 10.1093/ajh/hps011
22. Jiang, J. G., Ning, Y. G., Chen, C., Ma, D., Liu, Z. J., Yang, S.,et al. (2007). Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Res. 67, 6665-6674. doi: 10.1158/0008-5472.CAN-06-3643
23. Johansson, M., Herlitz, H., Jensen, G., Rundqvist, B., and Friberg, P. (1999). Increased cardiovascular mortality in hypertensive patients with renal artery stenosis: relation to sympathetic activation, renal function, and treatment regimens. J. Hypertens. 17, 1743-1750. doi: 10.1097/00004872-199917120-00012
24. Keserü, B., Barbosa-Sicard, E., Popp, R., Fisslthaler, B., Dietrich, A., Gudermann, T.,et al. (2008). Epoxyeicosatrienoic acids, and the soluble epoxide hydrolase are determinants of pulmonary artery pressure, and the acute hypoxic pulmonary vasoconstrictor response. FASEB J. 22, 4306-4315. doi: 10.1096/fj.08-112821
25. Kim, S., and Iwao, H. (2000). Molecular, and cellular mechanisms of angiotensin-II mediated cardiovascular, and renal diseases. Pharmacol. Rev. 52, 11-34.
26. King, L. M., Gainer, J. V., David, G. L., Dai, D., Goldstein, J. A., Brown, N. J.,et al. (2005). Single nucleotide polymorphisms in the CYP2J2, and CYP2C8 genes, and the risk of hypertension. Pharmacogenet. Genomics 15, 7-13. doi: 10.1097/01213011-200501000-00002
27. King, L. M., Ma, J., Srettabunjong, S., Graves, J., Bradbury, J. A., Li, L.,et al. (2002). Cloning of CYP2J2 gene, and identification of functional polymorphisms. Mol. Pharmacol. 61, 840-852. doi: 10.1124/mol.61.4.840
28. Krötz, F., Riexinger, T., Buerkle, M. A., Nithipatikom, K., Gloe, T., Sohn, H. Y.,et al. (2004). Membrane-potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arterioscler. Thromb. Vasc. Biol. 24, 595-600. doi: 10.1161/01.ATV.0000116219.09040.8c
29. Kujal, P., Čertíková Chábová, V., Škaroupková, P., Husková, Z., Vernerová, Z., Kramer, H. J.,et al. (2014). Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats. Clin. Exp. Pharmacol. Physiol. 41, 227-237. doi: 10.1111/1440-1681.12204
30. Lee, C. R., Imig, J. D., Edin, M. L., Foley, J., DeGraff, L. M., Bradbury, J. A.,et al. (2010). Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure, and attenuates hypertension-induced renal injury in mice. FASEB J. 24, 3770-3781. doi: 10.1096/fj.10-160119
31. Lorthioir, A., Guerrot, D., Joannides, R., and Bellien, J. (2012). Diabetic CVD-soluble epoxide hydrolase as a target. Cardiovasc. Hematol. Agents Med. Chem. 10, 212-222. doi: 10.2174/187152512802651042
32. Manhiani, M., Quigley, J. E., Knight, S. F., Tasoobshirazi, S., Moore, T., Brands, M. W.,et al. (2009). Soluble epoxide hydrolase gene deletion attenuates renal injury, and inflammation with DOCA-salt hypertension. Am. J. Physiol. Renal Physiol. 297, F740-F748. doi: 10.1152/ajprenal.00098.2009
33. Marciante, K. D., Totah, R. A., Heckbert, S. R., Smith, N. L., Lemaitre, R. N.,et al. (2008). Common variation in cytochrome P450 epoxygenase genes, and the risk of incident nonfatal myocardial infarction, and ischemic stroke. Pharmacogenet. Genomics 18, 535-543. doi: 10.1097/FPC.0b013e3282fd1287
34. McGiff, J. C., and Quilley, J. (1999). 20-HETE, and the kidney: resolution of old problems, and new beginnings. Am. J. Physiol. 277, R607-R623.
35. Merabet, N., Bellien, J., Glevarec, E., Nicol, L., Lucas, D., Remy-Jouet, I.,et al. (2012). Soluble epoxide hydrolase inhibition improves myocardial perfusion, and function in experimental heart failure. J. Mol. Cell. Cardiol. 52, 660-666. doi: 10.1016/j.yjmcc.2011.11.015
36. Michaelis, U. R., Fisslthaler, B., Barbosa-Sicard, E., Falck, J. R., Fleming, I., and Busse, R. (2005). Cytochrome P450 epoxygenases 2C8, and 2C9 are implicated in hypoxia-induced endothelial cell migration, and angiogenesis. J. Cell Sci. 118, 5489-5498. doi: 10.1242/jcs.02674
37. Minuz, P., Jiang, H., Fava, C., Turolo, L., Tacconelli, S., Ricci, M.,et al. (2008). Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. Hypertension. 51, 1379-1385. doi: 10.1161/HYPERTENSIONAHA.107.105395
38. Minuz, P., Patrignani, P., Gaino, S., Degan, M., Menapace, L., Tommasoli, R.,et al. (2002). Increased oxidative stress, and platelet activation in patients with hypertension, and renovascular disease. Circulation 106, 2800-2805. doi: 10.1161/01.CIR.0000039528.49161.E9
39. Oni-Orisan, A., Alsaleh, N., Lee, C. R., and Seubert, J. M. (2014). Epoxyeicosatrienoic acids, and cardioprotection: the road to translation. J. Mol. Cell. Cardiol. 74C, 199-208. doi: 10.1016/j.yjmcc.2014.05.016
40. Panigrahy, D., Edin, M. L., Lee, C. R., Huang, S., Bielenberg, D. R., Butterfield, C. E.,et al. (2012). Epoxyeicosanoids stimulate multiorgan metastasis, and tumor dormancy escape in mice. J. Clin. Invest. 122, 178-191. doi: 10.1172/JCI58128
41. Panigrahy, D., Greene, E. R., Pozzi, A., Wang, D. W., and Zeldin, D. C. (2011). EET signaling in cancer. Cancer Metastasis Rev. 30, 525-540. doi: 10.1007/s10555-011-9315-y
42. Pokreisz, P., Fleming, I., Kiss, L., Barbosa-Sicard, E., Fisslthaler, B., Falck, J. R.,et al. (2006). Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction, and pulmonary vascular remodeling. Hypertension 47, 762-770. doi: 10.1161/01.HYP.0000208299.62535.58
43. Powell, P. K., Wolf, I., Jin, R., and Lasker, J. M. (1998). Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2, and CYP4A11. J. Pharmacol. Exp. Ther. 285, 1327-1336.
44. Sinal, C. J., Miyata, M., Tohkin, M., Nagata, K., Bend, J. R., and Gonzalez, F. J. (2000). Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J. Biol. Chem. 275, 40504-40510. doi: 10.1074/jbc. M008106200
45. Spector, A. A. (2009). Arachidonic acid cytochrome P450 epoxygenase pathway. J Lipid Res. 50, S52-S6. doi: 10.1194/jlr. R800038-JLR200
46. Spiecker, M.1., Darius, H., Hankeln, T., Soufi, M., Sattler, A. M., Schaefer, J. R.,et al. (2004). Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 110, 2132-2136. doi: 10.1161/01.CIR.0000143832.91812.60
47. Sudhahar, V., Shaw, S., and Imig, J. D. (2010). Epoxyeicosatrienoic acid analogs, and vascular function. Curr. Med. Chem. 17, 1181-1190. doi: 10.2174/092986710790827843
48. Sun, D., Cuevas, A. J., Gotlinger, K., Hwang, S. H., Hammock, B. D., Schwartzman, M. L.,et al. (2014). Soluble epoxide hydrolase-dependent regulation of myogenic response, and blood pressure. Am. J. Physiol. Heart Circ. Physiol. 306, H1146-H1153. doi: 10.1152/ajpheart.00920.2013
49. Theken, K. N., Schuck, R. N., Edin, M. L., Tran, B., Ellis, K., Bass, A.,et al. (2012). Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease. Atherosclerosis 222, 530-536. doi: 10.1016/j.atherosclerosis.2012.03.022
50. Wang, D., and Dubois RN. (2012). Epoxyeicosatrienoic acids: a double-edged sword in cardiovascular diseases, and cancer. J. Clin. Invest. 122, 19-22. doi: 10.1172/JCI61453
51. Wang, X., Ni, L., Yang, L., Duan, Q., Chen, C., Edin, M. L.,et al. (2014). CYP2J2-derived epoxyeicosatrienoic acids suppress endoplasmic reticulum stress in heart failure. Mol. Pharmacol. 85, 105-115. doi: 10.1124/mol.113.087122
52. Weintraub, N. L., Fang, X., Kaduce, T. L., VanRollins, M., Chatterjee, P., and Spector, A. A. (1999). Epoxide hydrolases regulate epoxyeicosatrienoic acid incorporation into coronary endothelial phospholipids. Am. J. Physiol. 277, H2098-H2108.
53. Xu, X., Zhang, X. A., and Wang, D. W. (2011). The roles of CYP450 epoxygenases, and metabolites, epoxyeicosatrienoic acids, in cardiovascular, and malignant diseases. Adv. Drug Deliv. Rev. 63, 597-609. doi: 10.1016/j.addr.2011.03.006
54. Yu, Z., Xu, F., Huse, L. M., Morisseau, C., Draper, A. J., Newman, J. W.,et al. (2000). Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ. Res. 87, 992-998. doi: 10.1161/01.RES.87.11.992
55. Zhang, L. N., Vincelette, J., Cheng, Y., Mehra, U., Chen, D., Anandan, S. K.,et al. (2009). Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 29, 1265-1270. doi: 10.1161/ATVBAHA.109.186064